ORCTL3 is a member of a group of genes, the so-called anticancer genes, that cause tumour-specific cell death. We show that this activity is triggered in isogenic renal cells upon their transformation independently of the cells' proliferation status. For its cell death effect ORCTL3 targets the enzyme stearoyl-CoA desaturase-1 (SCD1) in fatty acid metabolism. This is caused by transmembrane domains 3 and 4, which are more efficacious in vitro than a low molecular weight drug against SCD1, and critically depend on their expression level. SCD1 is found upregulated upon renal cell transformation indicating that its activity, while not impacting proliferation, represents a critical bottleneck for tumourigenesis. An adenovirus expressing ORCTL3 leads to growth inhibition of renal tumours in vivo and to substantial destruction of patients' kidney tumour cells ex vivo. Our results indicate fatty acid metabolism as a target for tumour-specific apoptosis in renal tumours and suggest ORCTL3 as a means to accomplish this.
INTRODUCTION
Recent studies have led to the emergence of a new class of genes with a specific anticancer activity. Upon ectopic expression these factors cause the specific destruction of tumour cells by various forms of cell death such as apoptosis, autophagy or mitotic catastrophe, while normal cells are spared. Among those genes are apoptin, mda-7/IL-24, par-4 and also TRAIL. [1] [2] [3] [4] [5] Some of the factors are in clinical trials and show promising results. 6 Their modes of action are currently under intense investigation fuelled by the expectation that they reveal novel therapeutic interference options. We have recently presented ORCTL3 as one of the members of this growing, functionally-defined gene family that we collectively named 'anticancer genes'. 6 ORCTL3 was isolated in a systematic screen for such genes and its transfection into numerous tumourigenic cells induced apoptosis, while normal and primary cells remained healthy. 7 How this is accomplished remained unknown.
Recently, the metabolism of tumour cells has intensely been studied for differences to normal cells with the expectation that this will lead to novel targets and treatment options. 8, 9 Several studies indicated that fatty acid metabolism is changed in malignant cells, which is mainly interpreted as a consequence of the increased requirement of lipids for their excessive proliferation. 10 Indeed, most conventional anticancer compounds target actively proliferating cells and their efficiency, as well as their side effects, are correlated with enhanced proliferation. However, many tumour cells, in particular cancer stem cells, do not feature changes in their proliferation rate. Hence, the usefulness of targeting fatty acid metabolism for tumour treatment is currently unknown.
Renal cancer is the fourteenth most common cancer worldwide, with an estimated 273 500 new cases diagnosed in 2008. So far the therapy of renal tumours relies mainly on surgery and there is hardly any systemic drug treatment that can be used against advanced renal tumours. 11 The majority of tumours eventually become refractory even to novel targeted therapies. 12 The survival rate is only~50% within the first 5 years after diagnosis. Hence, there is an urgent need to discover novel treatment options.
Here, we show that ORCTL3 is activated for apoptosis induction when renal cells become transformed, independently of the proliferation status of the cells. For its apoptosis effect ORCTL3 targets stearoyl-CoA desaturase (SCD), an enzyme that introduces a double bond in the fatty acid stearic acid. We have found that ORCTL3 exerts its tumour-specific effect on renal cancer cells in vitro, in vivo and ex vivo.
RESULTS

ORCTL3 is activated for apoptosis induction by transformation
We chose an isogenic system of transformed versus normal renal cells to implement the most stringent test for ORCTL3's tumour specificity. To focus on a proven transformation system we turned to the primate renal CV-1 cells, which have extensively been used in the past and become transformed by individual tumourigenic mutations. 13 The sequencing of kidney cancer genomes has revealed considerable genetic inter-and intra-tumour heterogeneity of renal tumours. 14, 15 Because of this we asked whether ORCTL3 can target changes emerging from renal cell transformation per se rather than changes based on specific mutations found in sub-populations of renal tumours. We transfected these cells with myc, an activated allele of H-ras, and also with a mutant allele of p53, which establish cell transformation by various signalling pathways and have previously been connected with at least some human kidney cancers. [16] [17] [18] We also transfected the viral oncogenes E6 and E1A that have long been used for a partial transformation of cells. 19 To avoid introducing a bias by picking individual colonies, we used pools of transfected cells with a range of expression levels of the transfected genes to more accurately recapitulate the genetic heterogeneity in tumours. 20 These mutations caused morphological changes, ranging from profound, especially for H-ras and myc, which lost their contact inhibition, to more subtle changes such as for E1A, which mostly resembled their wild type (WT) CV-1 counterparts (Supplementary Figures  S1a and b) . Nevertheless, all tumourigenic mutations led to the immortalisation of the cells, while the parental CV-1 cells cease proliferation after about 10 passages. Transfection of WT CV-1 cells with a number of known pro-apoptotic genes such as RIP1, caspase-8, ANT1 and caspase-2 caused efficient cell death confirming the integrity of apoptosis signalling pathways in these cells ( Supplementary Figures S1c and S2) . The transformed as well as the WT CV-1 cells were then transfected with an expression construct for ORCTL3 and caspase-2 as a positive control. In parallel a fusion construct of ORCTL3 with an ER retention signal (ORCTL3-ER) was introduced that was found to generate higher apoptosis levels. 7 In the WT CV-1 cells we detected no appreciable apoptosis with both ORCTL3 constructs (Figure 1a) Figure S1a) . No further increase of apoptosis induction was observed with the ORCTL3-ER construct. In some of the transformed cells such as those transfected by H-ras the general apoptosis inducer caspase-2 was less efficient, in agreement with reports that attribute an apoptosis-inhibiting activity to this oncogene. 21 The lack of apoptosis induction in the WT CV-1 cells was not owing to a lower expression level of ORCTL3 in those cells. Rather, we detected a considerably higher transfection efficiency and consequently a higher expression of ORCTL3 in WT CV-1 cells than in their transformed counterparts (Figures 1g  and h) .
We compared ORCTL3 with the other anticancer genes apoptin, par-4 and mda-7/IL-24. Like ORCTL3, they remained ineffective for Figure S3g) .
As a first step to determine the cell characteristics that underlie ORCTL3's specificity we assessed the proliferation status of WT and transformed CV-1 cells and found that in an MTT assay only myc-transformed cells seemed to replicate slightly faster than WT CV-1 cells. All other tumourigenic mutations caused a slower proliferation (Figure 2a) . Cell cycle analysis revealed that cells with tumourigenic mutations, with the exception of E1A, had a reduced population of cells in the G1 phase and an increase in subG1 cells indicating that some of them underwent spontaneous apoptosis (Figure 2b ). ORCTL3 causes ARCosome activation and an incomplete ER-stress response We recently characterised the ARCosome, a caspase-8-activation complex that physically connects the ER with mitochondria and consists of mitochondrial Fis1 and Bap31 at the ER. 22 Upon recruitment of caspase-8 to the ARCosome, Bap31 is cleaved and activates downstream signals for apoptosis. ORCTL3 induces its apoptosis signal from the ER 7 and the physical proximity of the ARCosome to ORCTL3 led us to test the involvement of this apoptosis sensor. Co-transfection of ORCTL3 led to the cleavage of a fusion protein of Bap31-EYFP after 18 h (50%), a time point at which no overt apoptosis could be observed (Figures 3a and b and Supplementary Figure S4a) suggesting that it is an early event of the apoptosis signalling by ORCTL3. In agreement with this, when we individually inactivated the three components of the ARCosome, we observed a reduction of apoptosis induced by ORCTL3 (Figures 3c and d) . Moreover, ORCTL3 could interact with Bap31 in a co-immunoprecipitation experiment (Supplementary Figure  S4b) . However, transfection of the ARCosome activator Fis1 elicited cell death in WT CV-1 cells indicating that this complex is not exerting the tumour-specific effect. We previously observed an accumulation of the ER-stress sensor ATF4 but not of BiP/Grp78 as a signature of ORCTL3-transfected tumour cells. 7 We extended these results and also did not detect the upregulation of the proapototic transcription factor C/EBP homology protein, a ATF4-target gene in the canonical ER-stress response (Figure 3e ), while ATF3 was found to accumulate upon ORCTL3 expression (Supplementary Figure S4c) . The same ER-stress response was observed when we assessed Bap31, ATF4, ATF3 and BiP in H-ras-transformed CV-1 cells. Normal CV-1 cells, on the other hand, showed a much reduced Bap31 cleavage and no increase of the other ER-stress markers (Supplementary Figure S4d) . Nevertheless, in Hela cells the mRNA of XBP-1 was spliced upon ORCTL3 expression, a signal more proximal to the chaperone BiP (Figure 3f ). The knock down of ATF4 led to a weak but significant reduction of ORCTL3 apoptosis (Figure 3g ). These results indicate that some, but not all, consequences of canonical ER stress are instigated by ORCTL3 expression.
ORCTL3 targets SCD for tumour-specific apoptosis induction Downregulation of SCD has recently been revealed to cause apoptosis in lung and colon tumour cells lines, 23 which is mediated by a cellular response that, like ORCTL3, leads to an incomplete ER-stress response with ATF4 upregulation but not BiP. 24 Because of this and since both the SCD and ORCTL3 proteins are localised to the ER membrane, we tested whether this enzyme is a target of ORCTL3 for apoptosis induction. We added BSA-complexed oleic acid, the enzymatic product of SCD, to the cells after they were transfected with ORCTL3 or caspase-2 as a control. ORCTL3-induced apoptosis in p53-and H-ras-transformed CV-1 cells was significantly reduced, while cell death caused by the upregulation of caspase-2, Bax and caspase-8 remained unaffected (Figure 4a and Supplementary Figures S5a and b) . The transformed Hela and 293T cell lines also showed a reduced apoptosis by ORCTL3 upon addition of oleic acid (Supplementary Figure S5c) . We observed an increase of p53-and H-rastransformed cells undergoing apoptosis over their normal WT CV-1 counterparts when an inhibitor of SCD1 (CAY10566) was applied ( Figure 4b ). The application of this SCD1 inhibitor also caused Bap31 cleavage in the H-ras-transformed CV-1 cells but not in the normal CV-1 cells (Supplementary Figure 5d) .
Furthermore, co-immunoprecipitation revealed an interaction between ORCTL3 and SCD as we could detect endogenous SCD1 by western blot when we immunoprecipitated overexpressed ORCTL3. Conversely, when the endogenous SCD1 was immunoprecipitated, we detected the overexpressed ORCTL3 as a discrete band, rather than a smear as detected in the input probably representing differentially glycosylated forms of the ORCTL3 transporter ( Figure 4c) . Moreover, the expression of both mouse and human ORCTL3 reduced the desaturation index (18:1n-9/18:0 ratio) in normal and transformed CV-1 cells, with the mouse gene being slightly more effective (Figure 4d ). The reduction of the desaturation index in H-ras transformed CV-1 cells was not a consequence of apoptosis induction as the pro-apopotic p20 Bap31 fragment did not lead to a significant change in the desaturation index. We also measured the fatty acid composition in normal and H-ras transformed CV-1 cells (Supplementary Figure  S5e) . Co-transfection of SCD1 reduced ORCTL3's apoptosis induction but not cell death by RIP, ANT1, p20 and par-4 expression ( Figure 4e and Supplementary Figures S5f and g ). We also observed the co-localisation of transfected mouse and human ORCTL3 with endogenous SCD1 (Supplementary figure S6) . These results indicated that SCD activity is required for the survival of transformed, but not WT CV-1 cells. In agreement with this, we found that the transformed CV-1 cells harbour an upregulated SCD1 compared with normal cells (Figure 4f ). We also tested the expression level of SCD5 and found a pronounced upregulation of this enzyme in H-ras transformed CV-1 cells (Supplementary Figure S7a) . Moreover, we detected an interaction between mouse and ORCTL3 with SCD5 ( Supplementary Figure 7b ).
ORCTL3's apoptosis induction is specific for the mouse gene and critically depends on transmembrane domains 3 and 4 The mouse ORCTL3 gene and its human homologue are 73% identical at the protein level (84% similarity). Surprisingly, when we transfected human ORCTL3, we did not detect appreciable apoptosis induction in transformed HeLa and 293T cells ( Figure 5a ). Even titration experiments revealed that the degree of cell death attainable with human ORCTL3 remained significantly below the mouse ORCTL3 (Supplementary Figure S8a) . We investigated the accumulation of the protein in transfected cells and found that mouse ORCTL3 was considerably more stable (Supplementary Figure S8b) . Moreover, the human ORCTL3 interacted slightly weaker than mouse ORCTL3 with SCD1 (Supplementary figure S8c). To determine whether it is the accumulation and interaction of the proteins or whether the mouse ORCTL3 also comprises unique pro-apoptotic sequences, we mapped the domain(s) responsible for this differential apoptosis effect starting with the smallest ORCTL3 deletion construct that still induces apoptosis comprising the 5 N-terminal transmembrane domains (TM5). 7 While only the construct TM5 caused apoptosis, construct TM2 was nevertheless expressed to an appreciable level as assessed by flow cytometry analysis to monitor sub-populations with various expression levels ( Figure 5b and Supplementary Figure S8d ). These data suggested that the TM domains 3, 4, and 5 are required for apoptosis induction. Since the construct TM3 was unstable, we focused our further finemapping on the TM domains 4 and 5. We found that when the TM5 was partially or fully deleted (TM5b, TM5c) or when the loop between the 5th and the 6th TM was deleted (TM5a), the protein was rendered unstable and inactive for apoptosis induction. A construct harbouring the first four TM domains (TM4) was even more efficient than the larger construct TM5 for apoptosis induction (Figure 5c ). Apoptosis correlated with the expression levels of the constructs (Supplementary Figure S8e) . The minimal construct TM4 could still be inhibited by SCD1 cotransfection (Supplementary Figure 8f) . Given that the first four TM domains were sufficient for apoptosis (TM4) and the first two TM domains were stable but not active for apoptosis, we concentrated in a new round of mapping experiments on the third and the forth TM domain. It is known that during protein synthesis pairs of TM domains are co-inserted into the ER membrane. 25 However, neither the two TM domains on their own (TM34) nor when fused to the N-terminal signal sequence of ORCTL3 (NTM34), or when attached to two arginine residues, which when flanking α-helical transmembrane domains ensure their correct orientation in the membrane (NPosTM34), could elicit apoptosis (Supplementary Figure S8g) . All of these constructs were found not to be stable (Supplementary Figure S8h) .
We speculated that the two TM domains from mouse ORCTL3 could enable human ORCTL3 to initiate apoptosis when put into the human sequence context. ORCTL3 targets SCD for apoptosis induction G AbuAli et al panel) reveals that the chimera (DSTM3&4) caused apoptosis as efficiently as the mouse ORCTL3. The stability of the construct was substantially increased over the human ORCTL3 (Supplementary Figure S8i) . A sequence comparison indicated that both TM domains comprise a number of amino acids that differ between mouse and human and that the loop between the two TMs contains one exchange (Supplementary Figure S8j) . We swapped the TMs individually and converted the loop domain of the human ORCTL3 into the mouse sequence (Supplementary Figure S8k) . None of these constructs were capable of apoptosis induction or accumulated to an appreciable level (Figure 5d right bottom panel). When we inserted the two human TM domains into the mouse ORCTL3 gene (DSTM3&4HtoM), despite its expression level being comparable with the mouse protein (Supplementary Figure S8l) , only a very modest apoptosis was observed (Figure 5d , right bottom panel). We then asked whether apoptosis is a consequence of an incompatibility of the mouse ORCTL3 protein in a human cellular environment but the mouse ORCTL3 gene was also active for cell death in mouse N2a cells, in which it also accumulated to a higher level than its human equivalent (Supplementary Figure S9 ).
An ORCTL3-expressing adenovirus causes tumour growth inhibition in vivo and retains its specificity for malignant cells explanted from patients As the above mapping results highlighted the requirement of sufficient accumulation of ORCTL3 for apoptosis induction, we used an adenovirus vector, which can express genes to high levels. Based on our observation that ORCTL3, when retained at the ER, is more efficient for apoptosis, 7 as also detected with the TM4 deletion mutant (Supplementary Figure S10a) , we inserted an ORCTL3-ER construct into the adenovirus genome. We first adjusted the infection conditions so that we achieved equal expression in WT CV-1 cells and the E1A-transfected variants. The same titres were then used to express ORCTL3 in the other transformed cells. Figure 6a shows that ORCTL3 still did not cause cell death in the non-transformed CV-1 cells but all transformed cells showed considerable cell death after 24 h, including the E1A-transformed CV-1 cells that had not responded to the transfection of the ORCTL3 expression plasmid (Figure 1f) . When the extent of apoptosis was normalised to the expression levels (Supplementary Figure S10b) , it became evident that ORCTL3 could induce cell death in 91% of myc-transformed CV-1 cells, in 72% of E6-transformed cells, 50% of H-ras-transformed celss, 55% of p53-transformed cells, 20% of E1A-expressing cells and none in the WT CV-1 cells (Figure 6b ). This efficiency and specificity was supported by the apoptosis effects when the cells were infected twice, which likewise did not indicate any toxicity in the WT CV-1 cells (Supplementary Figure S10c) . To evaluate the effects of ORCTL3 in an in vivo xenograft model we made use of the human clear cell renal carcinoma cells Caki-2. In vitro experiments showed that these cells succumb to cell death upon ORCTL3 expression by the adenovirus, particularly when infected repeatedly ( Supplementary Figures S10d and e) . As many as 2 × 10 6 of these cells were injected into the flanks of nude mice and after the tumours reached approximately 50 mm 3 the ORCTL3-expressing adenovirus or a luciferase control virus were injected once every 6 days and the size of the tumours was determined. Figure 6c and Supplementary Figures S10f and g show that in all tumours ORCTL3 inhibited growth compared with the increase in tumour size seen with the luciferase control over a period of 6 weeks after which the animals were killed.
The ORCTL3-expressing adenovirus was then used on explanted primary renal tumour and normal cells obtained from the same patient. A total of six tissue specimens (three from normal cortex and three from advanced kidney cancers of Fuhrman grade 3) were maintained in culture. Clear cell renal cell carcinoma was diagnosed by a specialised pathologist in all cases upon inspection of the tissues taken from the same tumorous lesions used for the primary cell cultures. Similar to what has been reported 26 normal kidney epithelial cells showed higher proliferation rates than tumour cells and displayed a homogeneous population of cells with cobblestone appearance, while clear cell renal cell carcinoma cells displayed flattened polygonal morphology and many lipid vesicles in the cytoplasm (Figure 6d) . The required concentration of the virus was optimised by infecting normal and tumour cells and examining the expression of ORCTL3 or GFP (Supplementary Figure S10h) . Figure 6e shows that in primary tumour cells from all patients, ORCTL3, caused a specific apoptosis-inducing signal (27, 22 and 23% cell death) but exerted negligible toxicity in normal renal cells.
DISCUSSION
Anticancer genes have attracted considerable interest based on the expectation that the specificity of their proteins would aid in defining their mode of action and reveal additional targets in cancer treatment. For some anticancer genes, such as apoptin and par-4, several aspects of their downstream signalling have been elucidated. 27 ,28 For ORCTL3 we identified here an effector-the fatty acid metabolism enzyme SCD-as a target responsible for ORCTL3's tumour-specific pro-apoptotic effect in renal tumours. This connection was discovered based on ORCTL3's activation of an incomplete ER-stress response, which comprises the activation of ATF4 but not BiP (Figure 3e) , and which was also found when SCD was downregulated to initiate apoptosis. 24 This cell death was found to cause the demise of all tested tumour cells in one 24 but not in another study 23 suggesting that the cellular transformation scenario in which this enzyme can be targeted had not yet been established.
We have found kidney cancers as a tumour model that responds to the inhibition of this metabolic enzyme. This was indicated when individual tumourigenic mutations were introduced into renal cells in an otherwise isogenic cell system (Figures 1, 6a and b) and when kidney tumours were studied ex vivo (Figure 6e ). Previous work from our group had already shown that ORCTL3 is nontoxic to primary renal cells. 7 So far the therapy of renal tumours relies mainly on surgery. As they often do not respond to chemotherapy and radiotherapy, there is hardly any systemic treatment against disseminated renal tumours. 11 Consequently, renal tumours constitute a model in which conventional drugs are failing and only recently targeted therapy treatments against VEGF and mTOR have been approved for clear cell renal cell carcinoma cells. Nevertheless, the vast majority of tumours eventually also become refractory. 12 Studies on changes in the metabolism of cancer cells currently define a dynamic field. The commonly held view is that the increase in the proliferation makes it imperative for malignant cells to alter the metabolism of ATP production, macromolecule synthesis, redox status and fatty acids. Because of their increased proliferation, tumour cells are thought to become dependent on (addicted to) desaturated fatty acids through their increased requirement of phospholipids that constitute membranes. 10 Our results represent a new paradigm as the cells with tumourigenic mutations did not feature an increased proliferation rate (Figure 2 ) but nevertheless became sensitive to the inhibition of the metabolic enzyme and succumbed to ORCTL3. Most established antineoplastic agents act against rapidly-proliferating cells, which, however, is one of the reasons why these compounds also exert considerable side effects in, for example, blood cells. Our data indicate that ORCTL3 does not merely target cells with a higher proliferation rate (Figure 2) . SCD catalyses the introduction of a double bond between carbons 9 and 10 of saturated fatty acids and in particular palmitic (16:0) and stearic (18:0) acid to yield the monounsaturated fatty acids palmitoleic (16:1) and oleic (18:1) acid, respectively. The presence of double bonds in fatty acids (FA) has been shown to increase the fluidity of the membrane, a feature that has been implicated in facilitating tumour and metastasis formation. 29, 30 However, how specific these effects are for tumour cells remained unknown. By comparing isogenic normal with transformed-renal cells we have shown here for the first time that inhibition of SCD is synthetic lethal with transformation by various tumorigenic mutations (Figures 1, 4b, 6a and b) . Interestingly, the transformation of these cells is also accompanied by the upregulation of its transcript (Figure 4f ) confirming this gene as a treatment target, even though this was not accompanied by an increase of the desaturation index (Figure 4d) .
The role of SCD in obesity has been the focus of many studies most of which concluded that targeted inhibition of SCD1 is effective in preventing diet-induced obesity 31 thus establishing SCD1 as a therapeutic target for this indication. This finding in combination with our data presented here suggests an interesting connection between obesity and cancer through SCD1. Various studies concluded that obesity was associated with an increased risk of developing cancer or metastasis. [32] [33] [34] The abnormally elevated levels of SCD1 linked to the metabolic alterations found in obesity, as well as diabetes, and the upregulated levels of SCD1 in cancer cells, suggest SCD1 to be a molecular link between cancer and obesity. 35 Its inhibition is positively correlated to preventing obesity 31 and in this study we propose that its inhibition by ORCTL3 overexpression also results in specific toxicity to renal cancer cells.
We found ORCTL3 in a complex with Bap31 (Supplementary Figure S4b) , a component of the previously identified ARCosome 22 and its apoptosis induction depends on the components of this protein complex (Figures 3c and d) . Various results presented here indicate that the tumour-specific effect of ORCTL3 is accomplished through SCD inhibition and that the activation of the ARCosome is a downstream effect. The pro-apoptotic cleavage product of Bap31 cannot be inhibited for apoptosis induction by SCD1 cotransfection (Supplementary Figure S5g) and does not impact on the desaturation index (Figure 4d ). Also, caspase-8, which is activated in the ARCosome, 22 is not inhibitable by the addition of oleic acid and is not tumour-specific (Supplementary Figure S5b) .
High affinity compounds against SCD have been already developed. In agreement with the assumed higher specificity of anticancer genes and their encoded proteins, in vitro ORCTL3 elicited higher apoptosis and lower nonspecific activity (background in normal tissue) than the high affinity SCD1 inhibitor CAY10566 (Figures 4b and 6b) . For a therapeutic application of ORCTL3 it is essential to efficiently introduce the gene into target cells. This is evident by the increased apoptosis exerted by the adenovirus expressing ORCTL3 (Figures 1 and 6 ) and the difference between the human and the mouse ORCTL3, which seems to be caused by the increased stability in combination with a higher affinity to SCD1 of the mouse protein in cells ( Figure 5,  Supplementary Figure S8c) . The stronger apoptosis activity of mouse ORCTL3 was reflected by a slightly increased reduction of the desaturation index (Figure 4d) suggesting that a critical enzyme inhibition has to be reached for cell death. The ORCTL3-expressing adenovirus was more efficient in vitro (Supplementary Figure S8e) than in vivo (Figure 6c ) in reducing the tumour cells. However, the haemorrhagic tissue observed in the tumours could have obscured the in vivo effects, as indicated by the more pronounced size difference when the tumours were removed from the animals (Supplementary Figure S10g) . Gene therapy of tumours is still evolving but has recently made progress 36 and this work establishes proof of concept and biological validation of an ORCTL3-based therapeutic application.
Previously we found that ORCTL3 is downregulated in a number of tumours suggesting that it is a tumour suppressor gene, which when re-expressed in tumour cells, reconstitutes a pro-apoptotic pathway that is initiated by oncogenes. However, since the human ORCTL3 is less efficient for apoptosis induction, it is more likely that the overexpression of mouse ORCTL3 creates a neomorphic mutation in the tumour cells. The finding that the transfer of the 3rd and 4th TM domain from human to mouse retained its stability but did not lead to apoptosis (Figure 5d ) indicates that the two mouse TM domains have another function than just providing sufficient protein stability. This is a surprising finding as interactions with other proteins, if any, should be more conserved in the same species. Our data indicate that for high protein stability at least two mouse TM domains, either the 1/2 or the 3/4 pair in the correct context, are required. Accumulation within cells, however, is insufficient for efficient apoptosis induction as exemplified by the chimeric constructs with the human 3/4 TM domains (Figure 5d ). Hence, for efficient apoptosis the mouse TM domains 3/4 are necessary.
We have in this work focused on renal cancer, but our previous data indicate that ORCTL3 is active against a wide variety of cancers. 7 Future studies have to address the range of tumours that can be targeted with ORCTL3.
MATERIALS AND METHODS
DNA constructs
The mouse WT ORCTL3 and its ER fusion construct have been described. 7 Deletion mutants and domain swapping were generated using suitable primers and recombinant PCR with Phusion High-Fidelity DNA Polymerase (Finnzymes, Vantaa, Finland). PCR products were subcloned into the mammalian expression vector pcDNA3 (Invitrogen, Life Technologies, Carlsbad, CA, USA) and fused to an HA-tag at the C-terminal ends either by conventional restriction digestion and subsequent ligation using T4 DNA ligase (Promega, Madison, WI, USA) or by PCR Cloning using In-Fusion Advantage Kit (Clontech Laboratories, Inc., Mountain View, CA, USA). All subcloning products were sequenced to verify the correct sequence. Plasmid DNA was isolated using Invitrogen's maxi-prep kit according to the manufacturer's instructions. Human ORCTL3 and SCD1 complementary DNAs were obtained from OriGene Technologies, Inc. (Rockville, MD, USA).
Cell culture CV-1 cells (ATCC no: CCL-7), which are untransformed normal kidney fibroblasts, HeLa cells (ATCC no: CCL-2), HEK293T cells 7 and N2a cells (M.Sastre, Imperial College) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% foetal calf serum (Sigma-Aldrich). CV-1 cells were cotransfected by a plasmid containing the G418 resistance gene and an empty control vector or the gene of interest in a 1:9 ratio using Xfect transfection reagent (Clontech Laboratories, Inc.) and selected using 2.5 mg/ml G418 (Gibco, Life Technologies). HeLa cells were transfected with JetPEI (Peqlab, Erlangen, Germany) or Effectene (Qiagen, Venlo, Netherlands) and HEK293T cells were transfected with Xfect (Clontech Laboratories, Inc.) according to the manufacturer's instructions. All cell lines were validated by short tandem repeat DNA profiles before the start of the project.
MTT assay CV-1 cells were cultured in a 96-well plate at a density of 5 × 10 3 cells per well containing 100 μl complete phenol red-free DMEM medium (Sigma-Aldrich). 20 μl of 5 mg/ml MTT solution (Sigma-Aldrich) was added to each well and the manufacturer's protocol followed.
Cell cycle analysis
Cell cycle analysis was performed by propidium iodide staining and flow cytometry. Cells were cultured for 72 h in 24-well plates in complete DMEM. Cells were harvested, washed, and stained with propidium iodide lysis buffer (10 μg/ml propidium iodide (Sigma-Aldrich), 0.05% sodium citrate (Sigma-Aldrich), 0.05% Triton (Sigma-Aldrich) in phosphate-buffered saline). The fluorescent signal was detected with flow Cytometry and cell cycle distribution was analysed using Flowjo 7.6.2 software.
In vivo experiment
Caki-2 cells were obtained from ATCC and cultured in McCoy's 5A medium with 10% foetal calf serum. At 24 h and 4 h before inoculation, the cells in culture were fed with fresh medium. At the time of inoculation, cells were harvested and resuspended in media-free of serum and antibiotics, and kept under sterile conditions in sterile bijous. To form bilateral tumours, 2 × 10 6 cells were inoculated subcutaneously in a volume of 100 μl into the right and the left flank of each female nude mice. When tumour size reached 50-80 mm 3 ORCTL3-or luciferase-expressing adenovirus (50 μl of 5 × 10 9 viral particles) was injected intratumouraly once every 6 days to investigate the therapeutic potential of ORCTL3.
Collection and isolation of primary renal cells
Human kidney tissue samples were obtained from patients undergoing radical nephrectomy for renal cell carcinoma at Charing Cross Hospital (London). Tissue was collected from areas macroscopically identified as normal or tumourous immediately after extracting the specimen by an expert pathologist (tissue bank licence number 12275). Isolation procedure was performed within an hour of tissue removal according to an established protocol. 26 
Adenoviral infection
Three different adenoviruses (constructed and produced by Welgen, Inc, Worcester, MA, USA) were used expressing ORCTL3-ER complementary DNA, luciferase as a negative control and green fluorescent protein an infection efficiency control. Cells were plated at low density (20 × 10 3 cells per well of 24-well plate) and cultured overnight. On the day of infection, cells from one representative well were counted. Viruses at an original concentration of 1 × 10 12 virions/ml were diluted in 2% foetal calf serum DMEM to obtain the required multiplicity of infection. 200 μl of viruscontaining medium was added to the cells, which were incubated for 7 h. After which the cells were washed and kept in 10% DMEM until analysed. Primary renal carcinoma cells from patient #3 lacking the coxsackievirus and adenovirus receptor were infected with the help of AdBooster (Vector Biolabs, Philadelphia, PA, USA). The appropriate amount of the adenovirus was incubated with the recommended amount of the reagent in 2% foetal calf serum medium for 30 min at room temperature on a rotating wheel. The same procedure of the viral infection above was followed.
Immunofluorescence
Cells transfected with HA-tagged plasmids were fixed with 2% paraformaldehyde (Sigma-Aldrich) 24 h post transfection. Fixed cells were stained with Alexa flour 488-labelled monoclonal antibody against HA (Covance Inc., Princeton, NJ, USA) as described. 22 
Apoptosis quantification
Apoptosis in HeLa, HEK293T, CaKi2 and primary cells was quantified using 3,3'-dihexylocarbocyanine iodide (DiOC 6 )/propidium iodide double staining and flow cytometry as described. 37 Apoptosis in normal CV-1 and transformed CV-1 was determined by phenotype quantification as described. 7 For the fluorescein diacetate assay, harvested cells were resuspended in 200 μl of 2 μg/ml fluorescein diacetate (Sigma-Aldrich) in phosphate-buffered saline, incubated for 15 min at 37°C, and analysed on flow cytometer with excitation at 488 nm using FL1 channel (BD Biosciences, San Jose, CA, USA).
Cell lysate preparation
The cells were lysed in 100 μl radioimmunoprecipitation assay buffer (1% Nonidet P-40, 50 mM Tris pH 8 (Sigma-Aldrich), 150 m sodium chloride (Sigma-Aldrich), 0.1% SDS (Bio-Rad, Hercules, CA, USA), 0.5% deoxycholate (Sigma-Aldrich)) containing 1x protease inhibitor (Thermo Fisher Scientific, Waltham, MA, USA) and incubated on ice for 30 min. Cell lysates were centrifuged at 13 300 r.p.m. for 30 min at 4°C.
Western blot analysis
Using BCA protein assay (Sigma-Aldrich), equal amounts of proteins were denatured with 1X protein-loading buffer (Thermo Fisher Scientific) at 100°C for 10 min. Samples were electrophoresed in an SDSpolyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA) by semidry electroblotting (Bio-Rad) as described. 22 Membranes were probed with primary antibodies for H-Ras (1:200; sc-520, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), c-Myc (1:200; sc-789, Santa Cruz Biotechnology), p53 (1:500; sc-126, Santa Cruz Biotechnology), COX2 (1:1000; clone CX229, Caymann Chemicals), E6 (sc-460, Santa Cruz Biotechnology), E1A (1:1000, clone M73, Millipore), ATF4 (1:250, sc-200, Santa Cruz Biotechnology), C/EBP homology protein (1:1000, sc-7351, Santa Cruz Biotechnology), SCD1 (1:300, sc30435, goat polyclonal, Santa Cruz Biotechnology), β-actin (1:1000, A1978, Sigma-Aldrich), BiP (1:250, sc-1050, Santa Cruz Biotechnology), HA (1:1000, H6908 Sigma), SCD5 (AP53809PU-N, 2B Scientific Ltd, Oxfordshire, UK), ATF3 (sc-188(C-19), Santa Cruz Biotechnology), and against GAPDH (1:1500, sc-32233, Santa Cruz Biotechnology). The antibody against Bap31 was kindly provided by Dr Gordon Shore. Antibody binding was detected by enhanced chemiluminescence (Thermo Fisher Scientific) and visualised on film.
Coimmunoprecipitation
After harvesting the cells and washing them once with phosphatebuffered saline, they were lysed in 500 μl Tris/Triton buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 1% triton X-100) together with protease inhibitors on ice for 30 min Cell lysates were then processed as described 22 with the relevant antibody α-HA (H3663, mouse monoclonal, Sigma) (1:100) or α-SCD1 (sc30435, goat polyclonal, Santa Cruz Biotecnology) (1:100). Isotype-specific antibodies were used in the controls.
Fatty acid analysis
Total fatty acid composition of frozen CV-1 cells was determined by gas chromatography following total lipid extraction and transesterification according to Lepage and Roy 1986 with modifications 38 . Briefly, 1 ml of methanol/toluene (4:1) was added to frozen CV-1 pellets followed by vortexing and sonification. Acetyl chloride (100 μl) was added to cell lipid extract suspension then incubated for 2 h at 60°C. Extraction suspensions were cooled to room temperature and 2.5 ml of 6% K 2 CO 3 solution was added to each sample. The organic phase was then transferred to gas chromatography vials, evaporated to dryness under a stream of nitrogen then dissolved in 300 μl of n-hexanes. Samples were then analysed by gas chromatography (Agilent Technologies, Berkshire, UK; GC-7890A) equipped with a BPX70 capillary column (SGE, Analytical Science, Milton Keynes, UK; 25 m x 0.22 mm (ID) and 25 μm film thickness). Fatty acid composition was expressed as a percentage of the total of all fatty acids (weight % or wt%).
Statistical analysis
Statistical analysis was performed using the unpaired student's t-test. Data were obtained from n>3 experiments for every figure unless otherwise specified and were regarded as statistically significant if Po 0.05 (*), 0.01 (**) and 0.001 (***) based on student's t-test.
